Arain, F., Gullestad, L., Nymo, S., Kjekshus, J., Cleland, J. G, Michelsen, A., McMurray, J. J, Wikstrand, J., Aukrust, P. & Ueland, T. (2017). Low YKL-40 in chronic heart failure may predict beneficial effects of statins: Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). Biomarkers,22(3 to 4), 261-267. United Kingdom: Taylor and Francis Ltd. Retrieved from https://doi.org/10.1080/1354750X.2016.1204003
ABSTRACT Context and objective: To evaluate if YKL-40 can provide prognostic information in patients with ischemic heart failure (HF) and identify patients who may benefit from statin therapy. Materials and methods: The association between serum YKL-40 and predefined outcome was evaluated in 1344 HF patients assigned to rosuvastatin or placebo. Results: YKL-40 was not associated with outcome in adjusted analysis. In YKL-40 tertile 1, an effect on the primary outcome (HR 0.50, p¼0.006) and CV death (HR 0.54, p¼0.040) was seen by rosuvastatin in adjusted analysis. Conclusions: A beneficial modification of outcome was observed with statin therapy in patients with low YKL-40 levels.
Mary MacKillop Institute for Health Research
Access may be restricted.